Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

New studies show that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) cause almost as much weight loss as gastric ...

Smoothie King just launched a new "GLP-1 Support Menu" made specifically for people who take glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss and diabetes, such as Ozempic and Wegovy.

Prior to Ascendis, Novo signed a $600 million partnership with Metaphore Biotechnologies in May to develop two new GLP-1 receptor agonists. That deal is part of a larger partnership with venture ...

The new agreement grants Novo Nordisk an exclusive ... technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases.” ...

Recent developments in health sector include no longer needing to stop GLP-1 drugs before surgery, FDA warning against a California facility's compounded weight-loss drugs, resumption of Gaza polio ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

But Evanko said factors like the popularity of expensive new GLP-1 agonist anti-obesity drugs are driving up costs. "We've remained disciplined with our own pricing strategy," Evanko said.

As Ozempic continues to reshape the food industry, Smoothie King is responding with a new menu dedicated to Americans who use GLP-1 agonist drugs. It is the first instance of a quick-service ...

A new study reveals patients may continue to take their GLP-1 receptor agonists before undergoing elective surgery or endoscopy. The American Society for Metabolic and Bariatric Surgery reports ...